Impact of single‐nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD‐12/PRODIGE‐2 phase III trial-Reference-Cited by-同舟云学术

Impact of single‐nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD‐12/PRODIGE‐2 phase III trial

Published:2019-05-31 Issue:11 Volume:145 Page:3163-3172
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Boige Valérie¹²,Mollevi Caroline³⁴,Gourgou Sophie³⁴,Azria David⁵,Seitz Jean‐François⁶,Vincent Marc²,Bigot Ludovic⁷,Juzyna Beata⁸,Miran Isabelle⁷,Gerard Jean‐Pierre⁹,Laurent‐Puig Pierre²

Affiliation:

1. Department of Oncologic Medicine Gustave‐Roussy, Villejuif France

2. Université Paris Descartes; Paris Sorbonne Cité INSERM UMR‐S775 Paris France

3. Biometry UnitInstitut du Cancer Montpellier, Université de Montpellier Montpellier France

4. Institut de Recherche en Cancérologie de Montpellier Inserm U1194, Université de Montpellier Montpellier France

5. Department of Radiation Oncology, Institut du Cancer MontpellierUniv Montpellier, Inserm U1194 IRCM Montpellier France

6. Department of Digestive OncologyAix‐Marseille University, Assistance Publique Hôpitaux de Marseille Marseille France

7. Inserm U981, Gustave Roussy, Université Paris‐Saclay Villejuif France

8. Unicancer Paris France

9. Department of Radiation OncologyCentre Antoine Lacassagne, Université Côte d'azur Nice France

Funder

Institut National Du Cancer

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32417

Reference50 articles.

1. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer

2. Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

3. Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

4. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial

5. Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer;International Journal of Molecular Sciences;2023-12-20

2. 5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review);Oncology Reports;2023-08-07

3. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?;Frontiers in Pharmacology;2023-05-15

4. Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review;Cancers;2023-03-17

5. Biomarkers for Predicting the Response to Radiation-Based Neoadjuvant Therapy in Rectal Cancer;Frontiers in Bioscience-Landmark;2022-06-27